Active	Status	Sponsor type	Region	Phase	Filter
12 Active 7 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kaseb, Ahmed
BOSS-002, NCT05785390: Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.	Terminated	2	170	US	NP-101, TQ Formula, Placebo	Novatek Pharmaceuticals	COVID-19	05/25	05/25
NCT03897543: ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma	Recruiting	1/2	48	US	ABX196	Abivax S.A., C3 Research Associates	Carcinoma, Hepatocellular	06/21	06/23
Gutierrez, Anya
NCT04247542: ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection	Completed	2	53	US	Ibezapolstat, ACX-362E, Vancomycin, Vancomycin oral	Acurx Pharmaceuticals Inc.	Clostridium Difficile Infection	10/23	11/23
BOSS-002, NCT05785390: Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.	Terminated	2	170	US	NP-101, TQ Formula, Placebo	Novatek Pharmaceuticals	COVID-19	05/25	05/25
NCT05732610: MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study	Completed	N/A	34	US	MGC Health COVID-19 & Flu A+B Home Multi Test, MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)	Medical Group Care, LLC, CSSi Life Sciences	COVID-19, Influenza A, Influenza B	02/23	03/23
ARGONAUT, NCT04638751: Stool and Blood Sample Bank for Cancer Patients	Recruiting	N/A	5000	US	Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy	Persephone Biosciences	Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer	12/24	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kaseb, Ahmed
BOSS-002, NCT05785390: Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.	Terminated	2	170	US	NP-101, TQ Formula, Placebo	Novatek Pharmaceuticals	COVID-19	05/25	05/25
NCT03897543: ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma	Recruiting	1/2	48	US	ABX196	Abivax S.A., C3 Research Associates	Carcinoma, Hepatocellular	06/21	06/23
Gutierrez, Anya
NCT04247542: ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection	Completed	2	53	US	Ibezapolstat, ACX-362E, Vancomycin, Vancomycin oral	Acurx Pharmaceuticals Inc.	Clostridium Difficile Infection	10/23	11/23
BOSS-002, NCT05785390: Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.	Terminated	2	170	US	NP-101, TQ Formula, Placebo	Novatek Pharmaceuticals	COVID-19	05/25	05/25
NCT05732610: MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study	Completed	N/A	34	US	MGC Health COVID-19 & Flu A+B Home Multi Test, MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)	Medical Group Care, LLC, CSSi Life Sciences	COVID-19, Influenza A, Influenza B	02/23	03/23
ARGONAUT, NCT04638751: Stool and Blood Sample Bank for Cancer Patients	Recruiting	N/A	5000	US	Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy	Persephone Biosciences	Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer	12/24	12/25